S095029

Phase 2Small molecule

SServier Bio-Innovation LLC

S095029 is one of 106 small molecule programs targeting Non-small Cell Lung Cancer (NSCLC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

105

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung Cancer (NSCLC)Active, not recruiting

Colorectal CancerActive, not recruiting

Gastric CancerActive, not recruiting

Non-Small Cell Lung Cancer (NSCLC)Preclinical

Active, not recruiting

Colorectal CancerPhase 1

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Stivarga

Bayer

Phase 3

39 2

Opdivo

Bristol-Myers Squibb

Phase 3

24 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

37 4

Tecentriq

Roche

Phase 3

6 5

Mitosol

UUroGen Pharma Ltd.

Phase 3

1 6

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Phase 3

4 7

5-Fu

TToray Industries, Inc

Phase 3

3 8

SHR-A1811

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

1 9

Tucidinostat

CChipscreen Biosciences, Ltd.

Phase 3

1 10

TQB2102

CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalActive, not recruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT06162572

Clinical

Trials by Indication[1]

Gastric Cancer1 trial

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

Active, not recruiting·SServier Bio-Innovation LLC·Phase 1/2·NCT06116136·48 enrolled

Colorectal Cancer1 trial

S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

Active, not recruiting· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 1·NCT05162755·41 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression

Active, not recruiting·SServier Bio-Innovation LLC·Preclinical·NCT06162572·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for S095029. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — S095029 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for S095029. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Servier Bio-Innovation LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SServier Bio-Innovation LLC

S095029

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Gastric Cancer1 trial

Colorectal Cancer1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News